Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:36:45·⟳ 抓取 19:37:06 +21s·⚡ 决策 10-21 19:40:21 +3m15s·6.1 天前
ImmunityBio 完成 QUILT-2.005 Cohort A 膀胱癌试验数据库锁库，11 月公布 topline（程序性里程碑，无新增疗效数据）
本条 Investing.com 稿件是公司 2026-10-21 新闻稿的 AI 改写，与 72 小时内已处理的同一具体催化（ir_page 首发，11:37 UTC）完全一致：366 例锁库、11 月 topline、Q4 sBLA，未带来任何新增疗效数字、监管变化或金额。数据库锁库不产生新的临床/监管状态迁移，做多等于提前一个月裸赌二元读出，做空又面对中期分析阳性的正向基线，双向无正期望；盘前仅 +0.9% 也印证市场未给予预期差。
📄 原文Investing.com↗ 原文
ImmunityBio completes database lock for bladder cancer trial
CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ:IBRX) announced today the completion of database lock for Cohort A of i…
不做 ImmunityBio, Inc.（IBRX.US）
重复消息且无增量事实：数据库锁库是按计划推进的程序性里程碑，11 月 topline 与 Q4 sBLA 均为已知时间表，盘前仅 +0.9% 印证无预期差；做多是提前一个月裸赌二元读出，做空面对中期阳性基线，双向无正期望，待 topline 发布再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ImmunityBio 完成 QUILT-2.005 Cohort A 数据库锁库，但这是无新增疗效数据的程序性里程碑，topline 要等 11 月；同一公告刚被研判为不做，本条仅为转载改写，维持回避。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 medium · price-in 风险 high ↗
主要风险
- 真正催化是 2026 年 11 月的 topline 读出，结果二元且不可从锁库推断，届时需按完整 CR 率、DOR、p 值与安全性重新评估
反向证据
- 做空前查反向 · 来源 web · 日期 2026-10-21 · 影响 weakens
新闻稿重申 FDA 要求的中期分析显示 DOR 统计学显著延长，构成正向基线，做空缺乏强催化
检索:ImmunityBio ANKTIVA interim analysis duration complete response statistically significant FDA 原文 ↗
先例如何影响了这次决策
对本次决策的影响:同一具体催化已在 72 小时窗口内被研判且无新增事实，按查重早停不再重复检索先例；待 11 月 topline 真正发生时再补齐同机制临床读出先例
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,633 ms
{"result": "search_processed_events:agent query=`ibrx cohort a 366 patients database lock topline november 2026 sbla | immunitybio anktiva quilt-2.005 database lock bcg-naive bladder cancer | immunitybio 数据库锁定 膀胱癌 anktiva`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、22363 条本臂决策(完整)，返回 2 条候选。\n• 10-21 11:37 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 157 ms
{
原文全文
展开原文 · 2,155 字
CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ:IBRX) announced today the completion of database lock for Cohort A of its QUILT-2.005 trial, a randomized controlled study evaluating ANKTIVA in combination with Bacillus Calmette-Guérin versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer, according to a press release statement.
The database lock follows completion of data review, verification, and reconciliation of all 366 randomized patients enrolled in the trial. The study is designed to determine whether adding ANKTIVA to standard BCG therapy improves complete response rates compared with BCG alone.
An interim analysis requested by the U.S. Food and Drug Administration demonstrated statistically significant longer duration of complete response with ANKTIVA plus BCG compared to BCG alone. The final analysis is now underway and will assess the trial’s primary endpoint and key secondary endpoints, including duration of response.
ImmunityBio expects to report topline results in November 2026 and plans to submit a supplemental Biologics License Application to the FDA in the fourth quarter of 2026 for ANKTIVA plus BCG in patients with BCG-naïve NMIBC.
Cohort A completed enrollment in February 2026 with 366 patients randomized to receive ANKTIVA plus BCG versus BCG alone. In March 2026, following a protocol-specified interim review of data from 183 evaluable patients, the Independent Data Monitoring Committee determined that the enrolled population provided sufficient statistical power to detect the prespecified clinically meaningful difference between treatment arms, with no additional enrollment required.
ANKTIVA is currently approved in combination with BCG for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer. BCG-naïve patients are those receiving BCG-based therapy for the first time, representing an earlier stage of treatment than the BCG-unresponsive population.
The QUILT-2.005 trial enrolled patients across 110 U.S. and global clinical sites.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The database lock follows completion of data review, verification, and reconciliation of all 366 randomized patients enrolled in the trial. The study is designed to determine whether adding ANKTIVA to standard BCG therapy improves complete response rates compared with BCG alone.
An interim analysis requested by the U.S. Food and Drug Administration demonstrated statistically significant longer duration of complete response with ANKTIVA plus BCG compared to BCG alone. The final analysis is now underway and will assess the trial’s primary endpoint and key secondary endpoints, including duration of response.
ImmunityBio expects to report topline results in November 2026 and plans to submit a supplemental Biologics License Application to the FDA in the fourth quarter of 2026 for ANKTIVA plus BCG in patients with BCG-naïve NMIBC.
Cohort A completed enrollment in February 2026 with 366 patients randomized to receive ANKTIVA plus BCG versus BCG alone. In March 2026, following a protocol-specified interim review of data from 183 evaluable patients, the Independent Data Monitoring Committee determined that the enrolled population provided sufficient statistical power to detect the prespecified clinically meaningful difference between treatment arms, with no additional enrollment required.
ANKTIVA is currently approved in combination with BCG for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer. BCG-naïve patients are those receiving BCG-based therapy for the first time, representing an earlier stage of treatment than the BCG-unresponsive population.
The QUILT-2.005 trial enrolled patients across 110 U.S. and global clinical sites.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ad3499e8f9· 2026-10-21 19:40 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前